OBJECTIVE To explore the possible
role and mechanism of
vitamin D on the pathogenesis of
allergic rhinitis by adjuvant
therapy with
vitamin D3 .
METHODS A total of 60
allergic rhinitis patients and 30
healthy subjects were selected as the combination
therapy group, standard
treatment group and
control group .
Vitamin D3 nasal drops to
nasal cavity and oral Desloratadine
Citrate Disodium at the same
time 8.8 mg once a day were given in combined
treatment group
patients . Standard
treatment group
patients received oral Desloratadine
Citrate Disodium 8.8 mg once a day. The total
course of
treatment was 4 weeks and then to assess the changes of
serum 25(OH)D concentration,
eosinophils ,
IL-4 levels and the
therapeutic effect before and
after treatment . RESULTS The
serum 25(OH)D levels before and
after treatment in combination
therapy group were(23.67±4.47)ng/ml and (47.57±2.83)ng/ml, the
IL-4 levels were (14.576 ± 4.472)pg/ml and (10.381 ± 3.41l)pg/ml, and the
eosinophils of peripheral
blood counts were (0.71±0.14)× 109/L and (0.34 ± 0.09)×109/L. The total effective rate was 97%. The
serum 25(OH)D levels before and
after treatment in standard
treatment group were (23.42±3.83)ng/ml and(31.51 ±2.95)ng/ml, the
IL-4 levels were (15.187±5.144)pg/ml and (12.794 ±5.396)pg/ml, and the
eosinophils of peripheral
blood counts were (0.67±0.12)×109/L and (0.41 ±0.10)×109/L. The total effective rate was 84%. CONCLUSION Nasal
vitamin D3 drops combined with
antihistamines for
allergic rhinitis can effectively improve the clinical symptoms and reduce the related inflammatory markers.